Genetic moderators of naltrexone's effects on alcohol cue reactivity

John E McGeary1, Peter M Monti, Damaris J Rohsenow

  • 1Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island 02906, USA. John_McGeary@brown.edu

Abstract

Insights

Naltrexone’s effect on alcohol craving differs based on OPRM1 gene variations. Asp40 carriers experienced increased urge, while Asn homozygotes showed no change, suggesting personalized naltrexone treatment for heavy drinkers.

Area of Science:

  • Pharmacogenetics
  • Neuroscience
  • Addiction Medicine

Background:

  • Naltrexone (NTX) is used to reduce alcohol consumption and craving.
  • Genetic variations in dopamine D4 receptor (DRD4) and mu-opiate receptor (OPRM1) genes may influence NTX efficacy.
  • This study investigated these genes' role in moderating NTX's effect on alcohol craving in heavy drinkers.

Purpose of the Study:

  • To examine if OPRM1 and DRD4 gene polymorphisms moderate the effects of naltrexone on alcohol cue-elicited urge.
  • To investigate potential patient-treatment matching strategies for naltrexone therapy.

Main Methods:

  • Utilized data from 93 participants in a larger medication study, focusing on those consenting to genetic testing.
  • Genotyped participants for DRD4 variable number tandem repeat and OPRM1 Asn40Asp single nucleotide polymorphism.
  • Assessed alcohol cue reactivity 10 days after randomization to naltrexone (50 mg) or placebo.

Main Results:

  • Naltrexone increased alcohol urge in OPRM1 Asp40 carriers but had no effect in Asn homozygotes.
  • Asp40 carriers showed greater decreases in blood pressure compared to Asn carriers.
  • No significant effects of DRD4 gene polymorphisms on naltrexone response were observed.

Conclusions:

  • OPRM1 gene variation significantly influences individual responses to naltrexone regarding alcohol craving.
  • These findings may help reconcile conflicting results from naltrexone clinical trials.
  • Highlights the potential for personalized medicine approaches in treating heavy drinking.

Related Concept Videos

CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...